Among patients with melanoma that has metastasized (spread) to the liver, the Delcath PHP System™ appears to provide effective treatment to the liver. Full results from a Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
The liver is a common site of cancer metastasis. Effective treatment of liver metastases can improve survival in some patients, and researchers continue to explore new approaches to treating the liver.
The Delcath PHP System delivers very high doses of the chemotherapy drug melphalan directly to the liver via the hepatic artery. As the drug leaves the liver, the Delcath system collects and filters it. This minimizes exposure of the rest of the body to the drug, and allows for higher doses to be administered to the liver. The Delcath PHP System is still investigational, and continues to be investigated in clinical trials.
Partial results from a Phase III clinical trial of the Delcath PHP System were recently made available. The study enrolled melanoma patients with liver metastases that could not be surgically removed. Patients were treated with the Delcath PHP System or best alternative care.
Understanding DNA Damage Response or DDR and Cancer Treatment
What is DNA Damage Response or DDR?
The Delcath PHP System significantly delayed cancer progression in the liver. The median time to cancer progression in the liver was 214 days among patients treated with the Delcath PHP system compared with 70 days among patients treated with best alternative care.
Full results from this study will be presented in June at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
Reference: Delcath Systems Inc. Delcath Phase III Trial Results Exceed Primary Endpoint Expectations. Available at: delcath.com/index.php/news/171-delcath-phase-iii-trial-results-exceed-primary-endpoint-expectations.html Accessed April 22, 2010.